Neurotrophic Keratitis (NK) Therapy
We offer a novel topical treatment for ocular degeneration that restores neuronal function and vision with a simple eye drop.
The Problem
Neurotrophic Keratopathy (NK) is a degenerative corneal disease caused by impairment of corneal sensory innervation. It is characterized by decreased or absent corneal sensation, leading to epithelial breakdown, impairment of healing, and ultimately to the development of corneal ulceration, melting and perforation. The progression of the corneal degradation leads to an increased risk of eye infections that accelerate corneal destruction. It affects mostly a population of 60 years and older with increasing incidence. Currently treatments are able to delay disease progression, but ultimately corneal replacement is required.
The Solution
This novel treatment for NK offers a glycopeptide-based topical treatment that stimulates neuronal function and thereby promotes healing of the affected areas and preserves ocular function and vision. The treatment has shown to be effective in in vitro investigations and related glycopeptides have shown good systemic activity in vivo. Their endogenous inspiration allows to efficiently and rationally target neurobiological processes and pharmacology.
The Opportunity
The NK market is currently about $5 billion with a projected growth of about 5% per year. The only available pharmaceutical treatment is Oxervate, Recombinant Nerve Growth Factor, with a high price point. The newly offered therapeutic can be anticipated to obtain orphan drug designation which will facilitate clinical studies and approval.
The availability of related glycopeptides offers the opportunity of a broader platform solution and branching into other indications.
Status
The technology is in early stages of pharmacological validation. Similar compounds have been successfully investigated for neurodegenerative diseases and traumatic brain injury, providing a solid environment for this genus.
Meet the Team
Robin Polt PhD
College of Science
Peter Nestler PhD
Tech Launch Arizona
Contact us today.
Check out more Pharma startups.
View All Startups & Inventions
Precision anti-infective technology focused on a microbiome sparing strategy. We target Clostridioides difficile infection (CDI), an antibiotic-associated infectious diarrheal disease, through oral delivery of a targeted Antisense Oligonucleotide.
Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.
After a venomous snake bite time is of the essence. We enable immediate bite treatment that delays the neurotoxic and tissue damaging effects of the venom, allowing time to seek help.
Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).
